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Objective. Microvesicles (MVs) are small cell-derived particles shed upon activation. Familial hypercholesterolemia (FH)
particularly when associated with Achilles tendon xanthomas (ATX) predisposes to atherosclerosis, possibly through oxLDL-
C interaction with the CD36 receptor. To investigate the hypothesis that MVs derived from cells involved in atherosclerosis are
increased in FH and that CD36 expressing MVs (CD36+ MVs) may be markers of oxLDL-C-induced cell activation, cell-specific
MVsweremeasured in FHpatients with andwithoutATX and their associationwith atherogenic lipid profile was studied.Approach
and Results.Thirty FH patients with and without ATX and twenty-three controls were included. Plasma concentrations ofMVs and
CD36+ MVs derived from platelets (PMVs), erythrocytes (ErytMVs), monocytes (MMVs), and endothelial cells (EMVs), as well
as tissue factor-positive cells (TF+ MVs), were measured by flow cytometry. Total MVs, MMVs, EMVs, ErytMVs, and TF+ MVs
were significantly increased in FH patients, compared to controls. CD36+ MVs derived from endothelial cells and monocytes
were significantly higher in FH patients and oxLDL-C predicted all the investigated cell-specific CD36+ MVs in FH patients
with ATX. Conclusions. MVs derived from cells involved in atherosclerosis were increased in FH and may contribute to elevated
atherothrombosis risk. The increased cell-specific CD36+ MVs observed in FH may represent markers of oxLDL-C-induced cell
activation.
1. Introduction
Familial hypercholesterolemia (FH) is an autosomal domi-
nant genetic disorder associated with elevated levels of low-
density lipoprotein-cholesterol (LDL-C), cholesterol deposits
in tendons (xanthomas), and premature heart disease [1, 2].
The presence of tendon xanthomas (TX) is a marker of
increased cardiovascular disease risk among patients with FH
[3, 4]. Although the underlying mechanisms are not entirely
understood, proatherogenic modifications of lipoproteins
such as oxidized LDL-cholesterol (oxLDL-C) have been
attributed to important roles in both TX development [5, 6]
and scavenger receptor CD36-mediated atherosclerosis [7–
10].The activating/cytotoxic effect of oxLDL-Chas previously
been described [11, 12] and more recent studies demonstrate
a relationship between proatherogenic factors, including
oxLDL-C, and the shedding of submicronmembrane vesicles
[13–16]. These cell-specific microvesicles (MVs) are shed
from themembrane of activated circulating and vascular cells
[17, 18] and have in recent years received attention due to their
potential involvement in inflammatory and autoimmune dis-
eases, as well as in cardiovascular disorders and themetabolic
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syndrome [19–22]. They express markers from their parental
cell and harbormembrane and cytoplasmic proteins aswell as
bioactive lipids implicated in a variety of cellularmechanisms
[23]. Circulating MVs may therefore be looked upon as
biomarkers, providing information about their cellular origin
as well as the condition of the parental cell, and as active play-
ers in disease development and progression [24–26]. CD36
is expressed on various types of cells involved in processes
leading to atherosclerosis.
We hypothesize that circulating MVs derived from cells
involved in atherosclerosis development are increased with
elevated atherosclerosis risk in FH. In particular, we propose
that MVs expressing CD36 may be markers of oxLDL-
C-induced cell activation potentially leading to cholesterol
accumulation in the vessel wall. To explore this hypothesis,
circulating cell-specific MVs were measured in hypercholes-
terolemic FH patients with and without Achilles tendon
xanthomas (ATX). Furthermore, the potential association
between oxLDL-C and the presence of cell-specific CD36-
positive MVs was studied.
2. Materials and Methods
2.1. Study Subjects. The study group comprising thirty
patients (18 females and 12 males) genetically diagnosed
with heterozygous FH and twenty-three healthy controls (15
females and 8 males) as indicated by a medical questionnaire
has previously been described [6]. FH patients were selected
on the presence (11 females and 5 males) or absence (7
females and 7 males) of ATX, according to medical records.
None of the participants were taking medication at inclusion,
except lipid-lowering therapy, which was withdrawn 8 weeks
before study start. The study was conducted in agreement
with the Helsinki II declaration and approved by the Central
Denmark Region Committees on Health Research (2010-
0147) and by the Danish Data Protection Agency (j. number
2010-41-4879). The presence of ATX was confirmed by ultra-
sonographic measurements as described in [6].
Blood pressure, height, and body weight were recorded
and blood samples were obtained in the fasting state. The
following parameters were determined in the routine lab-
oratory: platelet, leukocyte, and monocyte counts, as well
as hemoglobin levels were determined on a Sysmex XE-
5000TM Automated Hematology System in ethylenediaminete-
traacetate (EDTA) blood. A Cobas® 6000 analyzer (Roche)
was used for analysis of glucose, alanine-aminotransferase
(ALT), triglycerides, total cholesterol (Total-C), low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), and apolipoprotein B (ApoB) in lith-
ium-heparin plasma. LDL-C concentrations were estimated
from the Friedewald formula [27].
2.2. Determination of oxLDL-C Levels. EDTA plasma for
measurement of oxLDL-C was stored at −80∘C until being
assayed. The Mercodia ELISA assay (Mercodia, Uppsala,
Sweden) used for oxLDL-Canalysismeasures bothminimally
and fully oxidized LDL-C particles. The intra- and interassay
coefficients of variation were 5.5–7.3% and 4.0–6.2%, respec-
tively, according to the manufacturer.
2.3. Flow Cytometric Measurement of Analysis Microvesicles in
Plasma. MV subpopulations were detected and quantitated
by a previously reported method [28]. Blood samples for MV
preparation were collected into sodium citrate anticoagulant
at a 3.2% (0.105M) final concentration and processed within
1 hour. Platelet-free plasma (PFP) was prepared by serial
centrifugations (10min. at 1800×g, 15min. at 3000×g, and
5min. at 3000×g), frozen, and stored at −80∘C until analysis.
For each analysis, 50𝜇Lof freshly thawedPFPwas transferred
to a TruCountTM tube (BD Biosciences, New Jersey, USA)
containing a lyophilized pellet, which releases a known
number of fluorescent beads, used for MV quantification fol-
lowing the manufacturer’s instructions. Subsequently, MVs
were labeled by adding 10 𝜇L fluorescein isothiocyanate-
(FITC-) conjugated Lactadherin (83𝜇gmL−1, Haematologic
Technologies Inc., Vermont, USA) [29, 30], characterized by
a phosphatidylserine- (PS-) bonding motif [29, 30].
To identify the cellular origin of MVs the following fluo-
rescent mAbs to specific cell surface markers were added
immediately after Lactadherin-FITC labeling: 8 𝜇L Allophy-
cocyanin- (APC-) conjugated anti-human CD41 (6𝜇gmL−1
IgG1, 𝜅 (clone HIP8, BioLegend, San Diego, CA, USA))
was used to detect platelet-derived MVs (PMVs), 5𝜇L anti-
human CD235a-APC (3 𝜇gmL−1 IgG2b, 𝜅 (clone HIR2,
eBioscience, San Diego, CA, USA)) was used to detect
erythrocyte-derived MVs (ErytMVs), 8 𝜇L APC-conjugated
anti-human CD31 (50 𝜇gmL−1 IgG1, 𝜅 (clone WM59, BioLe-
gend)) and 3 𝜇L PerCP-conjugated anti-human CD42b
(400 𝜇gmL−1 IgG1, 𝜅 (clone HIP1, BioLegend)) were used
to detect endothelial cell-derived MVs (EMVs) which were
defined as particles positively labeled by CD31 mAbs (platelet
and endothelium surface antigen) and negative for CD42b
(platelet surface antigen) [31]. 5𝜇LPhycoerythrin- (PE-) con-
jugated anti-human CD36 (6.25 𝜇gmL−1 IgG2a, 𝜅 (clone 5–
271)) was used to detect CD36-positive MVs (CD36+ MVs)
and 20𝜇L Phycoerythrin- (PE-) conjugated anti-human
CD142 (12.5 𝜇gmL−1 IgG1, 𝜅 (clone HTF-1, BD Pharmingen,
New Jersey, USA)) was used to detect tissue factor-positive
MVs (TF+ MVs).
After 30min. of incubation (4∘C, in the dark), 250𝜇L
0.22𝜇m filtered PBS was added to each labeled sample.
Plasma samples were analyzed immediately after labeling
using a BD FACSAriaTM III High Speed Cell Sorter, which
incorporates three air-cooled lasers at 488, 633, and 407 nm
wavelengths, and equipped with BD FACSDivaTM software (v.
6.1.3). Logarithmic amplification was used for all channels
and isotype controls on plasma samples were used as negative
controls. For the detection of MVs an initial microvesicle-
size gate was established by pilot standardization experiments
using a blend of size-calibrated fluorescent beads, with sizes
ranging from 0.2-𝜇m (Invitrogen, Hellerup, Denmark) to
3.0-𝜇m (Megamix beads (0.5, 0.9, and 3.0-𝜇m), Biocytex,
Marseille, France). The upper limit of the MV gate was set
just above the size distribution of the 0.9-𝜇m beads in an
forward (FSC-A) and side scatter (SSC-A) setting (log scale)
using the “autogate” function inside the FlowJoTM (v. 8.8.7, Tree
Star, Inc., Oregon, USA) software. The lower limit was the
noise threshold of the instrument. This threshold was set at
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Table 1: Characteristics of study participants.
Characteristics Controls FH 𝑝 valuea FH ATX− FH ATX+
𝑝 valueb
(𝑛 = 23) (𝑛 = 30) (𝑛 = 14) (𝑛 = 16)
Men/women 8/15 12/18 NS 7/7 5/11 NS
Age (years) 47.0 ± 10.1 45.5 ± 9.1 NS 43.1 ± 10.2 47.5 ± 7.8 NS
BMI (kg/m2) 23.7 ± 3.3 25.5 ± 5.2 NS 25.1 ± 4.2 25.9 ± 5.9 NS
Systolic b.p. (mmHg) 120.2 ± 10.8 124.9 ± 14.3 NS 122.4 ± 13.7 127.1 ± 14.8 NS
Diastolic b.p. (mmHg) 74.6 ± 6.7 77.4 ± 6.5 NS 76.0 ± 5.5 78.7 ± 7.1 NS
Platelet count (109/L) 239.8 ± 50.7 248.6 ± 60.1 NS 247 ± 55.7 250 ± 65.4 NS
Leukocyte count (109/L) 5.1 ± 1.2 5.4 ± 1.9 NS 5.0 ± 1.6 5.7 ± 2.2 NS
Monocyte count (109/L) 0.4 ± 0.1 0.5 ± 0.1 NS 0.4 ± 0.1 0.5 ± 0.2 NS
Hemoglobin (mmol/L) 8.7 ± 0.6 9.0 ± 0.8 NS 9.1 ± 1.0 8.9 ± 0.7 NS
Total-C (mmol/L) 5.1 ± 0.7 9.1 ± 1.8 <0.0001 8.2 ± 1.1 9.9 ± 2.0 0.0098
LDL-C (mmol/L) 2.9 ± 0.5 7.0 ± 1.8 <0.0001 6.0 ± 1.1 7.9 ± 1.8 0.0025
HDL-C (mmol/L) 1.7 ± 0.4 1.5 ± 0.4 0.014 1.5 ± 0.5 1.4 ± 0.4 NS
oxLDL-C (U/L) 50.0 ± 11.8 100.3 ± 24.2 <0.0001 83.7 ± 13.6 114.8 ± 22.1 0.0001
ApoB (g/L) 0.8 ± 0.1 1.7 ± 0.4 <0.0001 1.4 ± 0.3 1.8 ± 0.3 0.0015
Glucose (mmol/L) 5.4 ± 0.5 5.5 ± 0.4 NS 5.5 ± 0.4 5.5 ± 0.4 NS
ALT (U/L) 19.0 (14.0–21.0) 19.0 (17.0–34.0) NS 20.5 (18–32) 18.5 (15.0–36.5) NS
TG (mmol/L) 1.0 (0.8–1.2) 1.1 (0.8–1.8) NS 1.3 (0.7–1.8) 1.1 (1.0–1.6) NS
Normal and nonnormal distributions are shown as the mean ± standard deviation and as the median (interquartile range), respectively. aControls versus
FH subjects; bFH subjects without ATX versus FH subjects with ATX. BMI, body mass index; ALT, alanine-aminotransferase, TG, triglycerides; ApoB,
apolipoprotein B; Total-C, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; oxLDL-C, oxidized LDL-C; b.p., blood pressure; NS,
nonsignificant.
the SSC-A parameter to prevent exclusion of the smallest
events.We definedMVs as particles that were less than 1.0𝜇m
in diameter, had positive staining for Lactadherin-FITC, and
expressed cell-specific markers. IncreasedMMV number has
previously been reported on the same FH study population
[6].
2.4. Statistics. Statistical analyses were carried out using the
STATA 11.2 statistical program (StataCorp LP, Texas, USA).
MV data were expressed as median (interquartile range) and
analyzed using nonparametric Mann-Whitney 𝑈 tests. Con-
tinuous variables with a normal distribution were expressed
as themean ± standard deviation and analyzed with Student’s
𝑡-test. Statistical correlation was analyzed using Spearman’s
rank correlation for nonnormal distributed data. Multiple
regression (robust) analysis was used to adjust for the
confounding effect of gender. The standardized regression
coefficients beta (𝛽) is included as a measure of how strongly
each predictor variable influences the criterion (dependent)
variable. Variables with nonnormal distribution were log-
transformed to achieve normal distribution before regression
analysis. Shapiro-Wilk’s𝑊 test was used to test the assump-
tion of normality. 𝑝 values are two-sided and considered
significant when <0.05.
3. Results
3.1. Characteristics of the Study Subjects. Table 1 shows the
clinical characteristics of the study participants. Total choles-
terol, LDL-C, and oxLDL-C were significantly increased in
FH patients compared to healthy controls, and HDL-C levels
were significantly lower. FH patients with ATX had signifi-
cantly higher concentrations of total cholesterol, LDL-C, and
oxLDL-C than FH patients without ATX, whereas HDL-C
levels were similar. All other laboratory measurements were
within age- and gender-specific reference intervals, and no
significant differences were observed between groups.
3.2. Analysis of MV Subpopulations in Patients with FH. FH
patients had higher concentrations of total MVs (𝑝 =
0.022), endothelial cell-derived MVs (EMVs) (𝑝 = 0.002),
erythrocyte-derivedMVs (ErytMVs) (𝑝 = 0.043),monocyte-
derived MVs (MMVs) (𝑝 = 0.004), and tissue factor-positive
MVs (TF+ MVs) (𝑝 = 0.006), when compared to healthy
controls (Table 2). No significant difference in platelet-
derived MVs (PMVs) was observed. As shown in Figure 1,
CD36+ MVs were derived from all the investigated cells
and most abundantly among MVs derived from platelets,
endothelial cells, and monocytes (Table 2). FH patients had
higher concentrations of CD36+ EMVs (𝑝 = 0.008) and
CD36+MMVs (𝑝 = 0.001), whereas no significant difference
in CD36+ PMVs, CD36+ ErytMVs, or total CD36+ MVs
was observed. The presence of ATX had no influence on MV
levels (data not shown).
3.3. Association between oxLDL-C and CD36-Positive MVs in
FHPatients with ATX. OxLDL-Cwas not correlatedwith any
of the investigated CD36+ MV subpopulations in healthy
individuals or in FH patients without ATX. In FH patients
with ATX, oxLDL-C showed strong correlations with total
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Table 2: Plasma levels of circulating MVs.
Controls (𝑛 = 23) FH (𝑛 = 30) 𝑝 value
Total MVs 15603 (10549–45211) 35616 (23409–58075) 0.022
Total CD36+ MVs 2161 (1274–3213) 2754 (1704–3772) NS
EMVs 157 (119–238) 282 (204–522) 0.002
CD36+ EMVs 143 (85–212) 212 (170–408) 0.008
PMVs 2020 (1387–2876) 1664 (1382–2773) NS
CD36+ PMVs 1758 (1229–2475) 1482 (1219–2482) NS
MMVs 5 (3–11) 10 (7–14) 0.004
CD36+ MMVs 3 (2–4) 5 (4–8) 0.001
ErytMVs 207 (147–282) 296 (193–453) 0.043
CD36+ ErytMVs 8 (3–13) 11 (6–15) NS
TF+ MPs 225 (204–396) 408 (327–451) 0.006
Values (MVs𝜇L−1 plasma) are shown as themedian (interquartile range).MVs,microvesicles;MMVs,monocyte-derivedMVs; EMVs, endothelial cell-derived
MVs; PMVs, platelet-derived MVs; ErytMVs, erythrocyte-derived MVs; CD36, scavenger receptor CD36; TF, tissue factor.
CD36+ MVs (Rho = 0.70, 𝑝 = 0.003), CD36+ EMVs (Rho
= 0.77, 𝑝 < 0.001), CD36+ PMVs (Rho = 0.74, 𝑝 = 0.001),
and CD36+ ErytMVs (Rho = 0.74, 𝑝 = 0.001), but not with
CD36+MMVs.No correlation between oxLDL-C andCD36-
negative subpopulations was observed in any of the three
study groups.
Gender-adjusted regression analysis demonstrated strong
associations between oxLDL-C and all the investigated
CD36-positiveMVs, including total CD36+MVs (𝑅2 = 0.76,
𝑝 < 0.001), CD36+ EMVs (𝑅2 = 0.68, 𝑝 < 0.001), CD36+
MMVs (𝑅2 = 0.41, 𝑝 = 0.027), CD36+ PMVs (𝑅2 = 0.64,
𝑝 < 0.001), and CD36+ ErytMVs (𝑅2 = 0.51, 𝑝 = 0.003) in
FH patients with ATX (Table 3).The associationwith oxLDL-
C remained significant for both CD36+ PMVs (𝑅2 = 0.70,
𝑝 = 0.004) and CD36+ MMVs (𝑅2 = 0.41, 𝑝 = 0.034) after
adjusting for platelet and monocyte count, respectively. TF+
MVs and oxLDL-C were significantly associated (𝑅2 = 0.26,
𝑝 = 0.031) in FH patients with ATX.
4. Discussion
The interest in cell-derived MVs and their potential role in
cardiovascular disease (CVD) is steadily increasing, as they
may not only reflect the presence of CVD but also play a
causative role in its development [32, 33]. This study shows
that FH patients have significantly higher concentrations of
overall circulating MVs and in particular higher concen-
trations of those derived from endothelial cells, monocytes,
and erythrocytes. Moreover, CD36+ MVs derived from
endothelial cells and monocytes were significantly higher in
FH patients compared to healthy controls. This study also
shows that among FH patients with ATX oxLDL-C was a
significant predictor of all the investigated subpopulations of
CD36+ MV, whereas MVs negative for CD36 were unrelated
to oxLDL-C levels. To the best of our knowledge this is
the first study investigating the impact of FH on level and
distribution of circulating MVs, in particular CD36+ MVs,
and directly addressing the relationship between plasma
levels of proatherogenic oxLDL-C and circulating CD36+
MV subpopulations.
Table 3: Multiple regression analysis with oxLDL-C and gender as
independent variables.
Controls FH ATX− FH ATX+
𝛽 𝑝 value 𝛽 𝑝 value 𝛽 𝑝 value
𝑅
2 = 0.05 𝑅2 = 0.03 𝑅2 = 0.76
Total CD36+ MVs
oxLDL-C −0.07 NS 0.16 NS 0.94 <0.001
Gender 0.18 NS −0.08 NS 0.53 0.004
𝑅
2 = 0.01 𝑅2 = 0.03 𝑅2 = 0.64
CD36+ PMVs
oxLDL-C −0.08 NS 0.11 NS 0.88 <0.001
Gender 0.04 NS −0.13 NS 0.32 NS
𝑅
2 = 0.09 𝑅2 = 0.16 𝑅2 = 0.41
CD36+ MMVs
oxLDL-C 0.06 NS 0.30 NS 0.58 0.027
Gender 0.33 NS 0.24 NS 0.60 0.024
𝑅
2 = 0.08 𝑅2 = 0.01 𝑅2 = 0.68
CD36+ EMVs
oxLDL-C −0.20 NS 0.02 NS 0.90 <0.001
Gender 0.14 NS −0.07 NS 0.39 0.041
𝑅
2 = 0.04 𝑅2 = 0.16 𝑅2 = 0.51
CD36+ ErytMVs
oxLDL-C −0.19 NS 0.26 NS 0.78 0.003
Gender 0.03 NS 0.28 NS 0.27 NS
The standardized regression coefficients beta (𝛽) is included as a measure
of how strongly each predictor variable influences the criterion (dependent)
variable. 𝑝 values are two-sided and considered significant when <0.05. See
Table 2 for abbreviations.
Elevated LDL-C is a well-known risk factor for athe-
rosclerosis and CVD [34]. Prolonged lipid exposure to cells
within the vascular compartments may trigger the release of
MVs in concordance with our observation of increased MV
concentrations in FH patients.
This is supported by a recent study demonstrating
reduced MV concentrations in FH patients after an effective
lipid-lowering treatment with statins [35]. When comparing
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Figure 1: Flow cytometric analysis of CD36-positive MVs derived from various cell types. MVs were identified by size (<1 𝜇m) and by
surface exposure of phosphatidylserine. Colabeling with cell-specificmarkers identified CD36 expressingMVs (colored red) from various cell
types, including (a) CD36+ CD41+ (platelet-derived) MVs, (b) CD36+ CD235a+ (erythrocyte-derived) MVs, (c) CD36+ CD14+ (monocyte-
derived) MVs, and (d-e) CD36+ CD31+/CD42b− (endothelial cell-derived) MVs identified by a two-color method. CD31 is expressed on
both platelets and endothelial cells, whereas CD42b is restricted to platelets, allowing discrimination between PMVs and EMVs (colored
blue). Right columns correspond to the respective isotype controls.
FH patients to non-FH hypercholesterolemic patients MV
concentration was higher in the former indicating that
both degree and length of exposure affect MV release [36].
Together, these results indicate that overall MVs have the
potential of being a marker of hyperlipidemic atherosclerosis
risk.
Cell-specific MVs may have some value as markers for
the ongoing processes within the vascular compartment, as
reported in [23, 37–39]. The finding herein of increased
EMV concentrations in FH patients may therefore indicate
endothelial cell activation and dysfunction. The increased
MMV concentrations most likely reflect activation of inflam-
matory cells, whereas increased ErytMV concentrations may
be associated with prothrombotic risk. Although our study
cannot prove causality because of its cross-sectional nature
the results presented herein may provide information about
the steady-state condition in the vascular compartment
during prolonged exposure to elevated LDL-C levels.
Monocyte-derived MVs are like endothelial-derived and
erythrocyte-derivedMVs significant sources of procoagulant
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activity due to their expression of tissue factor [40, 41], as
well as of phosphatidylserine, a cofactor in the coagulation
cascade [42]. Elevated levels of monocyte-derived TF+ MVs
observed in hyperlipidemia patients are suggested to con-
tribute to arterial thrombosis after rupture of atheroscle-
rotic plaques [42]. Moreover, Wang and colleagues recently
demonstrated that monocyte-derived MVs could activate
endothelial cells in an IL-1 beta-dependent manner [43]. The
observed higher concentrations of both MMVs and overall
TF+ MVs in FH patients may promote or even accelerate
atherothrombosis as suggested in [44].
The association between TF+ MMVs and oxLDL-C has
previously been demonstrated in acute coronary syndrome
[13]. Moreover, a recent study by Owens et al. reported
oxLDL-C-induced TF expression in THP-1 monocytic cells
and human monocytes and showed that FH patients had
elevated levels of both oxLDL-C and TF+ MV-associated
procoagulant activity [45].
The relationship between serum cholesterol and circu-
lating erythrocytes recently reported in 4,469 adult partic-
ipants of the National Health and Nutrition Examination
Survey (NHANES) [46] suggested that erythrocyte viability
is related to cholesterol levels. Erythrocyte membranes con-
tain a ratio of cholesterol and phospholipid, which affects
their deformability, and without a nucleus and organelles to
synthesize lipids, a large proportion of membrane cholesterol
content originates from plasma lipids [47]. Changes in shape
and deformability may lead to the production of ErytMVs
and increased concentrations in FH patients, as presented
herein. A possible consequence may be activation of the
vascular endothelium, resulting in vascular inflammation
and atherosclerosis as previously suggested [48].
Proatherogenic modifications of lipoproteins such as the
oxidation of LDL-C are attributed to important roles in the
atherogenic process.The activating effect of oxLDL-C causing
membrane vesiculation has been described in endothelial
cells [49], platelets [14], and monocytes [13, 50], and in a
previous published work from our group we reported that
high numbers ofMMVs are associatedwith proinflammatory
monocytes and oxLDL-C [6]. The binding of oxLDL-C to
CD36 is considered to trigger intracellular signaling events,
but the precise contribution of CD36 is still a matter of debate
[51, 52]. Knowing that CD36 expression is a common feature
of these cell types, we propose that oxLDL-C binding toCD36
may lead to cell activation and MV release. The increased
MV concentrations found in FH patients and the strong
association between CD36+ MVs and oxLDL-C in FH with
ATX suggest a possible involvement in processes leading to
endothelial dysfunction and cardiovascular risk.
This study has some limitations as we used 900 nm pol-
ystyrene microspheres from Megamix to define the upper
limit of a forward scatter MV size gate. Although this gating
strategy has been published by the ISTH Scientific Standard-
ization Committee [53, 54] the difference in refractive index
and thus forward angle light scatter between polystyrene
beads and cellular MVs must be taken into account, as stated
in a very recent study by van der Pol et al. [55].
In conclusion, increased circulating MVs, in particular
MMVs, EMVs, ErytMVs, and TF+ MVs, may contribute to
atherosclerosis development and elevated atherothrombosis
risk in patients with FH. The increased endothelial- and
monocyte-derived CD36+ MVs may reflect the state of
their parental cells and indicate oxLDL-C-induced activation
through a CD36-dependent mechanism. The association
between oxLDL-C and CD36+MVs in FH patients with ATX
suggests the involvement of lipoprotein-associated oxidative
stress in MV release. Thus, although the prognostic potential
of circulating MVs is still in its infancy, our findings indicate
that detection and quantification of MV subpopulations,
especially CD36+ MVs, may be a potentially valuable tool
for risk assessment and may add to a better understanding
of their potential contribution to vascular complications in
hypercholesterolemia.
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